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Immunization in Renal Transplant Recipients: 
Where Do We Stand?
Ankur Gupta, Sanjay Kumar Agarwal
Infections are a major cause of morbidity and mortality in renal transplant recipients. Adequate vaccination 
strategies can prevent a majority of them. This review highlights the various vaccines, their dosing, schedule, 
efficacy and safety in renal transplant patients. [Hong Kong J Nephrol 2010;12(1):6–11]
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INTRODUCTION
The survival and outcomes after renal transplantation 
have improved significantly over the last two decades. 
This has led to the need for effective preventative mea-
sures to maintain good health. Potent immunosuppres-
sive regimens mean that these patients are at higher risk 
of infections. Vaccines remain the only way to prevent 
the disease and replication of microorganisms. Renal 
transplantation leads to an immunosuppressed state and, 
even with vaccines, patients may not be able to mount 
a response that is as effective as that in normal subjects 
[1]. The fear of graft rejection may lead to avoidance 
of certain vaccines [2]. A transplant physician will have 
various concerns. Firstly, what effects will immunosup-
pressive medicines have on pretransplant vaccination 
status? Secondly, to what extent is a vaccine effective in 
the post transplant period? Thirdly, what are the side 
effects of the vaccines, and will they have any effect 
on graft function? Lastly, what type of vaccine should 
be used: live or inactivated ones? This review attempts 
to answer these questions and provide guidelines to 
specific vaccine-preventable diseases.
Awareness of the need for vaccination in organ 
transplant recipients is often lacking. In a transplant 
center in Berlin, it was found that immunization rates 
were too low in solid organ transplant patients and most 
patients (89%) were not adequately informed about 
immunizations; and if informed, the main sources of 
information were physicians (47%) and the media 
(40%). Seroprotection rates against tetanus were fairly 
high in liver and renal transplants and considerably 
lower for diphtheria, hepatitis A, and influenza. Health 
care providers need to be proactive in improving vac-
cination strategies [3].
VACCINATION STRATEGIES IN RENAL 
TRANSPLANTATION
Vaccination timing
Getting this right is critical for optimal response. In 
general, primary immunizations should be given before 
transplantation, as early as possible during the course 
of disease, since the immune response to vaccines is 
decreased in patients with end-stage organ disease [4]. 
The ﬁrst 6 months after transplantation are associated 
with the poorest response as patients are usually heavily 
immunosuppressed [5]. This period has also been as-
sociated with a higher chance of graft dysfunction and 
rejection. Vaccinating too close to transplantation may 
also result in ineffective protection. An initial reduction 
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in antibody titers immediately after vaccination has been 
described in children [6]. Experts suggest that vaccines 
should be administered no less than 6 months after solid 
organ transplantation, to permit sufficient time for the 
doses of immunosuppressants to stabilize and for the 
immune system to recover from cytolytic induction 
therapies [7].
Immunoadjuvants
The data on immunoadjuvants mainly come from 
hepatitis B vaccines. Interferon and interleukin-2 were 
used in the 1980s as adjuvants in low responders to 
hepatitis B vaccine [8,9]. Interleukin-2, in particular, 
was used in uremia patients with 70% seroconversion 
without major side effects. More recently, the compound 
MF59 has been used together with hepatitis B virus 
vaccine in normal adults with promising results [10]. 
There are no data available in immunocompromised 
patients for this compound. Furthermore, the safety of 
immunoadjuvants in patients post renal transplantation 
has yet to be established and the risk of rejection directly 
caused by immunoadjuvants needs to be excluded.
Monitoring of antibody titers
This could prove useful in transplant patients. Unprotected 
patients should receive additional doses of vaccines until 
adequate levels are achieved. The assays for antibody 
responses therefore need to be standardized [11].
Rejection risk
This is a theoretical concern in transplant settings. 
Viruses themselves, such as adenovirus and influenza 
B virus, are known to incite rejection [12]. Vaccination 
against them may be protective.
Live vaccines
Live vaccines are absolutely contraindicated in renal 
transplant recipients. They include live oral typhoid, 
oral polio, bacillus Calmette-Guerin, and vaccinia [4]. 
Whenever needed, killed parenteral typhoid Vi polysac-
charide vaccine and inactivated polio vaccine may be 
used. Oral polio vaccine is also contraindicated in the 
family members of transplant recipients because of 
possible contagion by shedding of the virus and close 
contact with excreta [13,14].
SPECIFIC VACCINES IN RENAL TRANSPLANT 
RECIPIENTS
Hepatitis B vaccine
Renal transplant recipients are known to have severe 
and rapid progression of hepatitis B. There is also con-
cern of reactivation of latent infection due to immuno-
suppression [15]. The hepatitis B vaccine usually 
provides good protection against infection. However, 
regardless of anti-HBs immunity, hepatitis B virus infec-
tion can occur in immunosuppressed patients who live 
in an endemic area. In a previous study, three 40-μg doses 
of vaccine to 17 patients who had previously undergone 
transplantation revealed a cumulative antibody response 
rate of only 17.6% at 12 months, and the three responders 
had low titers of antibody to hepatitis B surface antigen 
[16]. Thus, transplantation is associated with reduced 
efficacy of vaccine and intensive dosing is therefore de-
sired. Even after a 40-μg, four-dose schedule, only 32–36% 
of patients who are vaccinated after kidney transplanta-
tion experience seroconversion [17]. Among renal 
transplant recipients who respond to the primary vac-
cination series, a median of 70% have protective titers 
at 12 months, whereas healthy individuals achieve nearly 
complete protection [18]. Hepatitis B can develop after 
kidney transplantation when antibody levels become 
undetectable [18].
Currently, the US Advisory Committee on Immuni-
zation Practices recommends four doses of the 40 μg 
intramuscular vaccine at 0, 1, 2 and 6 month intervals 
[19]. The vaccine should be given as early as possible 
in the course of the disease to obtain the best response. 
Monitoring of titers can be useful in identifying those 
patients with antibody levels lower than 10 mIU/mL 
who are not protected against the infection [20]. A 
hepatitis B surface antibody test should be performed 
1–2 months after the last dose of vaccine, and repeated 
every 6–12 months following transplantation [21]. 
Additional booster doses and revaccination at intervals 
of 2–3 years have been proposed [15].
It has been noted that anemia, hepatitis C infection, 
elderly age, obesity and iron overload states are associated 
with decreased antibody response [18,22,23]. Adjuvants 
like erythropoietin, interferon-γ and granulocyte–
macrophage colony-stimulating factor have been used in 
renal failure patients [24]. However, data in transplant 
patients is unavailable and so they cannot be recommended 
at this time.
Hepatitis A vaccine
This vaccine is safe and well tolerated in renal transplant 
patients. A 6-monthly two-dose regimen is recom-
mended [25]. It was shown that only 24% of renal 
transplant patients compared to 90% of healthy controls 
experienced seroconversion after the first dose. After 
the second dose, up to 72% of renal transplant patients 
seroconverted [26]. Two years after transplantation, 74% 
of renal recipients who had been successfully immu-
nized had antibody titers below the protective level [27]. 
There are no clear guidelines for monitoring serologic 
response or revaccinations.
Influenza vaccine
Viral pneumonia caused by influenza is a potentially 
life-threatening infection. A study of 49 renal transplant 
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recipients indicated that, although antibody titers after 
vaccination were significantly lower than in vaccinated 
healthy controls, the incidence of influenza was similar 
in both groups [28]. On the contrary, recently, in 53 renal 
transplant recipients, it was found that the percentage 
of kidney transplant recipients developing a hemag-
glutination inhibition (HI) titer greater than 1:32 or 
having a four-fold increase in HI titer after inﬂuenza 
vaccination was lower than the percentage of healthy 
adults who did so, particularly within 6 months of trans-
plantation. In this study, the percentage of patients who 
developed HI titers greater than 1:32 ranged from 70% 
for the inﬂuenza A (H3N2) and inﬂuenza A (H1N1) an-
tigens to 86% for the inﬂuenza B antigen. Hence, clini-
cians should have a greater suspicion for susceptibility 
to inﬂuenza despite vaccination in this group [29]. Two 
or three doses of vaccine does not seem to provide ad-
ditional benefit over a single dose [30,31]. Most medi-
cal societies and experts recommend yearly influenza 
vaccination for renal transplant recipients, and monitor-
ing is not necessary.
The antibody responses in kidney transplant recipi-
ents receiving either azathioprine or mycophenolate 
were almost equal [32]. A similar rise in antibody titer 
occurred in sirolimus and calcineurin inhibitor treated 
patients, although sirolimus treated patients developed 
a “protective” titer to more influenza antigens. Hence, 
vaccination guidelines in place for calcineurin inhibitor 
treated patients are likely to be appropriate for transplant 
recipients maintained on sirolimus [33]. There was a 
concern that influenza vaccination of renal allograft 
recipients could be associated with de novo production 
and/or increased titers of anti-human leukocyte antigen 
antibodies. In a study of 66 stable renal transplant re-
cipients and 19 healthy volunteers during the 2005–2006 
vaccination campaign, vaccination was not associated 
with any significant change in preexisting or de novo 
anti-human leukocyte antigen sensitization. No episode 
of allograft rejection was recorded in any of the patients. 
The results suggest that flu vaccination is safe in stable 
post renal transplant patients [34].
The US Centers for Disease Control assessed the 
level of cross-reactive antibody to the novel influenza 
A (H1N1) virus in cohorts of children and adults before 
and after vaccination with the 2005–2009 seasonal in-
fluenza vaccines. In children, before vaccination, there 
were no cross-reactive antibodies to swine-origin influ-
enza virus A (H1N1) [S-OIV A (H1N1)]. Among adults, 
before vaccination, cross-reactive antibodies were de-
tected in 6–9% of those aged 18–64 years, and in 33% of 
those aged > 60 years. Previous vaccination of children 
with influenza vaccines did not elicit a cross-reactive 
antibody response to S-OIV A (H1N1). In adults aged 
18–64 years, vaccination with seasonal influenza vac-
cine resulted in a two-fold increase in cross-reactive 
antibody response to S-OIV A (H1N1), compared with 
a 12–19-fold increase in response to the seasonal H1N1 
strain. No increase in cross-reactive antibody response 
to S-OIV A (H1N1) was observed among adults aged 
> 60 years. These data suggested that receipt of recent 
(2005–2009) seasonal influenza vaccines did not elicit 
a protective antibody response to the novel influenza 
A (H1N1) virus [35].
Liang et al in China recruited nearly 12,700 indi-
viduals to evaluate pandemic vaccines in eight formula-
tions: 7.5 μg, 15 μg and 30 μg hemagglutinin, with or 
without aluminium hydroxide adjuvant, and adjuvant 
whole-virion vaccine containing 5 μg or 10 μg hemag-
glutinin. Seroconversion was deﬁned as a four-fold in-
crease in HI titer to at least 1:40, which is regarded by 
regulatory authorities as seroprotective. By day 21, one 
dose of the 7.5 μg, non-adjuvant, split-virion formula-
tion had induced seroprotection in 97% of adolescents 
(12 to < 18 years), 90% of adults (18–60 years), and 
80% of elderly adults (> 60 years) [36].
Plennevaux et al from the USA reported the prelimi-
nary results of a single dose of a pandemic H1N1 vaccine 
in two phase 2 placebo-controlled trials. Vaccine doses 
ranged from 7.5 μg to 30 μg for adults. Interim results 
indicated that 92–97% of the adults and 83–92% of 
the elderly participants seroconverted after one vaccine 
dose [37].
The HI assay is used as the standard for licensing 
inﬂuenza vaccines, but the correlation of a HI titer of at 
least 1:40 with seroprotection is based on work pub-
lished in 1984 which showed that a titer of 1:42 for 
H1N1 and 1:44 for H3N2 provided 50% protection 
against infection [38].
As immunosuppressed patients form a group that is 
more prone to develop severe manifestations of this 
virus, nephrologists around the world need to be more 
cautious. Renal transplant recipients could be one highly 
susceptible group for this infection [39]. However, the 
utility of this pandemic vaccine cannot be ignored in 
the present scenario.
Pneumococcal vaccine
Renal transplant recipients may develop severe Strep-
tococcus pneumoniae infection. Vaccination has been 
recommended in heart, renal and liver recipients. Avail-
able vaccines are the 23-valent polysaccharide (PPV23) 
and the heptavalent protein conjugate (PCV7). Both of 
them are safe and probably more effective before 
advanced renal failure sets in. There is no difference 
in their functional antibody responses as assessed by 
opsonophagocytic assay [40]. In a study comparing 
durability of response for patients enrolled in a random-
ized trial of PCV7 versus PPV23 pneumococcal vac-
cination, it was shown that vaccine responses decline 
significantly by 3 years and PCV7 vaccine does not 
improve the durability of response. The only factor that 
was predictive of response durability was a strong 
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multiserotype initial response [41]. Because boosting 
is more effective in pa tients who are immunized before 
transplantation, all transplant candidates should undergo 
pneumococcal vaccination. It is recommended that 
routine pneumococcal vaccination be done every 3–5 
years [25]. However, it was recently shown that dialysis 
and renal transplant patients rapidly lose their serum 
antibody levels during the 1 year after vaccination. 
Specifying protective levels for serum IgG and IgG2 
levels in these patients would help us to more precisely 
follow these patients and to consider revaccination when 
levels fall below the protective serum antibody level 
[42]. This vaccination policy may be useful for prevent-
ing invasive pneumococcal disease in immunosup-
pressed patients [43].
Human papillomavirus vaccine
The risk of cervical cancer in women who are kidney 
transplant recipients is increased, but little is known 
about the effectiveness of the human papillomavirus 
(HPV) vaccination in this group of women. In a study 
determining the cost-effectiveness of annual screening 
for cervical cancers and pretransplant HPV vaccination 
in kidney transplant recipients, it was found that a pro-
gram of HPV vaccination before kidney transplantation 
is unlikely to be cost-effective. Additional data about 
the long-term efficacy and safety of HPV vaccination 
is required before it should be included as standard care 
of renal transplant recipients [44]. However, the quadri-
valent HPV vaccine is not live; therefore, the theoretical 
risk of harm to transplant recipients is low [45].
Varicella vaccine
The varicella vaccine is a live attenuated virus and is 
therefore contraindicated in the transplant population 
[25]. All seronegative candidates should receive one 
dose of varicella vaccine before transplant, preferably 
at least 4 weeks prior. Cases of successful immunization 
of children with varicella vaccine after renal transplan-
tation have been reported, with one small study dem-
onstrating a 66% rate of conversion to high antibody 
titers [46,47]. However, the currently available clinical 
data are too scarce to recommend a live vaccine for adult 
renal transplant patients.
Tetanus, diphtheria and pertussis vaccine
Tdap, a combination vaccine containing tetanus and 
diphtheria toxoids and an acellular pertussis component 
is available. In one study of 164 renal transplant patients, 
13% of patients did not have protective titers to tetanus 
at baseline and over 31% did not have titers to diphthe-
ria. After Td (tetanus and diphtheria) booster vaccina-
tion, patients had lower antibody titers for both tetanus 
and diphtheria than did healthy controls. However, in the 
case of tetanus, nearly 100% of patients achieved protec-
tive titers after a single booster and the duration of 
immunity approximated that of controls. In contrast, 
only 89% of patients achieved protective antibody titers 
for diphtheria after the booster and this percentage 
dropped to 62% at 1 year. No difference was observed 
in antibody levels between patients on different immu-
nosuppressive drug regimens [48]. In another study, 
after booster immunization, the protection rate against 
diphtheria rose to 95% at 1 month, with a decline to 93% 
at 6 months and 76% at 12 months. Protection against 
tetanus was complete after vaccination and persisted 
over the observation period. Antibody concentrations 
were comparable to those reported for healthy children 
[49]. This led to the recommendation to routinely ad-
minister tetanus and diphtheria boosters at regular in-
tervals in patients after renal transplantation and to 
assess postvaccination titers every 5 years for tetanus 
and not later than 2 years after vaccination for diphthe-
ria. However, these recommendations may not always 
be applicable to adult patients [50].
CONCLUSIONS
Vaccination is an important means of preventing infec-
tions, and thereby decreasing morbidity and mortality 
in renal transplant recipients. The key principles in 
transplant immunization are as follows:
• immune response is best prior to transplantation;
• antibody response is usually decreased as compared 
to healthy subjects;
• protection can be lost earlier as compared to healthy 
subjects;
• side effects should be minimal;
• risk of rejection must be insignificant;
• live attenuated vaccines are generally contraindicated;
• awareness amongst transplant physicians is needed.
The current Kidney Disease: Improving Global Out-
comes (KDIGO) guidelines recommend certain vaccines 
after kidney transplantation (Table 1) and list contrain-
dicated vaccines (Table 2) [51]. Larger studies are 
needed for definitive statistical proof of the safety and 
effectiveness, with regard to the quality of the 
Table 1. Recommended vaccines after renal transplantation
Diphtheria-pertussis-tetanus
Haemophilus influenza B
Hepatitis A: for travel, occupational or other speciﬁc risk, and 
 endemic regions
Hepatitis B
Pneumovax: consider providing booster polysaccharide 
 pneumococcal vaccination every 3–5 years
Inactivated polio
Influenza types A and B ( administer annually)
Meningococcus: administer if recipient is at high risk
Typhoid Vi
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immune response, of vaccination strategies in renal 
transplant recipients.
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